Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children

NCT02899702 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no EC approval obtained

Conditions

Staphylococcal Infection
Streptococcal Infection

Interventions

DRUG: PRIVIGEN (CSL Behring)
DRUG: Albumin

Sponsor

Hospices Civils de Lyon